Fasudil is under clinical development by Woolsey Pharmaceuticals and currently in Phase II for Progressive Supranuclear Palsy .

Tolebrutinib is under clinical development by Sanofi and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS).

As the holidays come to a close, Progressive narrowly reclaimed the top spot on Media Monitors’ Radio Spot Ten for the week ...

Progressive (PGR) concluded the recent trading session at $241.02, signifying a -0.89% move from its prior day's close.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Speaking of insurance companies, Progressive(NYSE: PGR) is one of the best to do it. Decades ago, it was commonplace for insurers to break even on their policies with returns coming from their ...

The stock's fall snapped a three-day winning streak.

The lucky player won 100% of the $583,746 Progressive Jackpot by purchasing a winning $10, 50-Times-The-Money ticket at Jake’s Wines and Liquor on South Business Drive. The winning jackpot eclipsed ...

Raymond James upgraded EverQuote (EVER) to Strong Buy from Outperform with an unchanged price target of $35. While the ...

Raymond James raised its recommendation on the property and casual insurer Progressive (PGR), citing the stock to be a core ...

Progressive (NYSE:PGR – Get Free Report) was upgraded by analysts at Raymond James from a “market perform” rating to an ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $293.86, with a ...